Standout Papers
- The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial (2024)
- Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria (2022)
Citation Impact
16 standout
Citing Papers
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of Summer Xia being referenced
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
2024 Standout
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
2018
Author Peers
| Author | PRM | Oncology | RNMI | Immunology | Rheumatology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|---|
| Summer Xia | 22 | 40 | 16 | 102 | 72 | 11 | 206 | |
| Julie Charlesworth | 11 | 185 | ||||||
| L.H. Zetterberg | 11 | 49 | 1 | 14 | 1.3k | |||
| Ethan R. Block | 21 | 54 | 86 | 20 | 19 | 502 | ||
| Laetitia Vlaminck | 1 | 11 | 371 | |||||
| Helen S. Yee | 5 | 59 | 19 | 26 | 23 | 14 | 462 |
All Works
Loading papers...